Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia

Experimental Hematology & Oncology

Guoqing Wei¹  Yongxian Hu¹  Jiasheng Wang¹  He Huang¹  Lijuan Ding² 

[1] Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University;School of Medicine, Zhejiang University;

关键词: Acute lymphoblastic leukemia (ALL);    CD19;    Chimeric antigen receptor-modified T cell (CAR-T);    Conditioning regimen;    Complication;    Cytokine release syndrome (CRS);   

DOI  :  10.1186/s40164-017-0070-9

来源: DOAJ

【 摘 要 】

Abstract Refractory/relapsed B-cell acute lymphoblastic leukemia remains to be a significant cause of cancer-associated morbidity and mortality for children and adults. Developing novel and effective molecular-targeted approaches is thus a major priority. Chimeric antigen receptor-modified T cell (CAR-T) therapy, as one of the most promising targeted immunotherapies, has drawn extensive attention and resulted in multiple applications. According to published studies, CD19-directed CAR-T cells (CD19 CAR-T) can reach a complete remission rate of 94% in both children and adults with refractory/relapsed ALL, much higher than that of chemotherapy. However, the encouraging outcomes are often associated with complications such as cytokine release syndrome (CRS), serious neurotoxicity, and on-target off-tumor effect, which seriously impeded further clinical application of CAR-T cells. Moreover, CAR-T therapy is typically associated with high relapse rate. This article briefly reviews the manufacture technologies, the conditioning regimens, the cell infusion doses, as well as the prevention and treatment strategies of complications for CAR-T cell therapy.

【 授权许可】

Unknown